PerBiotiX - Microbiome Solutions: Company Profile
Background
Overview
PerBiotiX is a Slovak biotechnology startup specializing in the targeted and personalized modulation of the gut microbiome. Established by a team of experts with extensive experience in microbiome research, the company aims to enhance human health by developing innovative probiotic and prebiotic solutions.
Mission and Vision
The mission of PerBiotiX is to leverage years of research and a global network to create personalized probiotic and prebiotic products that address various health conditions linked to the gut microbiome. Their vision is to be a leading innovator in the field of microbiome modulation, contributing to the prevention and treatment of diseases through personalized approaches.
Primary Area of Focus
PerBiotiX focuses on the development of personalized probiotics, prebiotics, synbiotics, and flavobiotics under the brand iProbio. These products are designed to modulate the gut microbiome, aiming to improve health outcomes and address specific health concerns.
Industry Significance
The gut microbiome is recognized as a critical factor in human health, influencing various physiological processes and disease states. PerBiotiX's work positions it at the forefront of a rapidly growing biotechnology sector, contributing to the advancement of personalized medicine and microbiome-based therapies.
Key Strategic Focus
Core Objectives
PerBiotiX aims to develop personalized and targeted microbiome modulation products that can be integrated into supportive therapies for chronic and infectious diseases. The company seeks to utilize its research and international collaborations to create innovative solutions that address health issues where microorganisms play a key role.
Specific Areas of Specialization
The company specializes in:
- Personalized Probiotics: Tailored probiotic formulations based on individual microbiome analyses.
- Prebiotics and Synbiotics: Development of prebiotic and synbiotic products to support beneficial gut bacteria.
- Flavobiotics: Innovative products combining probiotics with bioactive compounds.
Key Technologies Utilized
PerBiotiX employs advanced microbiome analysis techniques to inform the development of its products. The company collaborates with academic institutions and utilizes cutting-edge research to create effective microbiome modulators.
Primary Markets or Conditions Targeted
The company's products target a range of health conditions, including:
- Chronic Diseases: Such as inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.
- Infectious Diseases: Particularly hospital-acquired infections like Clostridium difficile.
- Metabolic Disorders: Including obesity and diabetes.
- Allergies and Intolerances: Addressing conditions like lactose intolerance and food allergies.
Financials and Funding
Funding History
Specific details regarding PerBiotiX's funding history, total funds raised, and recent funding rounds are not publicly disclosed. The company has established collaborations with academic institutions and industry partners to support its research and development activities.
Notable Investors
Information about individual investors or venture capital firms backing PerBiotiX is not publicly available.
Intended Utilization of Capital
The capital raised is likely allocated towards:
- Research and Development: Advancing the development of personalized microbiome modulators.
- Clinical Trials: Conducting studies to validate product efficacy and safety.
- Market Expansion: Scaling production and distribution capabilities.
Pipeline Development
Key Pipeline Candidates
PerBiotiX's primary pipeline includes:
- iProbio Personalized Probiotics: Tailored probiotic formulations based on individual microbiome analyses.
Stages of Clinical Trials or Product Development
The company has initiated the development of personalized probiotics and is likely in the preclinical or early clinical stages of product development. Specific details regarding clinical trial phases are not publicly disclosed.
Target Conditions
The pipeline targets conditions such as:
- Gastrointestinal Disorders: Including IBD and infections like Clostridium difficile.
- Metabolic Diseases: Such as obesity and diabetes.
- Immune-Related Conditions: Including allergies and intolerances.
Relevant Timelines for Anticipated Milestones
Specific timelines for product development milestones are not publicly available. The company is expected to progress through preclinical studies, followed by clinical trials, with commercialization contingent upon successful outcomes.
Technological Platform and Innovation
Proprietary Technologies
PerBiotiX utilizes proprietary microbiome analysis techniques to inform the development of personalized probiotic and prebiotic products. The company collaborates with academic institutions to leverage cutting-edge research in microbiome science.
Significant Scientific Methods
The company employs advanced microbiome analysis methods to tailor probiotic formulations to individual needs. This personalized approach is based on comprehensive research and collaboration with scientific experts.
Leadership Team
Key Executive Profiles
- MVDr. Alojz Bomba, DrSc.: Scientific Director with over 40 years of experience in microbiome research, author of numerous publications, and holder of multiple patents. He is responsible for the scientific direction of the company.
- Ing. Norbert Bomba: Marketing and Business Development Manager
